{"filing":{"accession_number":"0001193125-26-391780","cik":"0001469443","ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-10","primary_document":"rkda-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526391780/rkda-20260910.htm"},"events":[{"id":33586,"run_id":30887,"accession_number":"0001193125-26-391780","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Arcadia Biosciences held its Annual Meeting of Stockholders on September 10, 2026, and reported voting results on seven proposals including director elections, equity issuance authorization, adoption of the 2026 Omnibus Equity Incentive Plan, reverse stock split authorization, advisory compensation vote, auditor ratification, and meeting adjournment.","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37069,"accession_number":"0001193125-26-391780","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Omnibus Equity Incentive Plan, a successor to the expired 2015 Plan. This is a compensatory arrangement for officers and directors involving equity grants and incentive awards. The filing explicitly references Item 5.02(e) context and describes the plan's governance and effectiveness, making it a material executive compensation disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T19:02:42.138124+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37070,"accession_number":"0001193125-26-391780","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Arcadia Biosciences' Annual Meeting held September 10, 2026. The filing reports final voting tallies on seven proposals including director election, equity issuance authorization, adoption of a 2026 Omnibus Equity Incentive Plan, reverse stock split authorization, advisory compensation vote, auditor ratification, and meeting adjournment. These results are material to investors as they reflect stockholder approval of significant corporate actions including potential dilutive equity issuances and reverse stock split authority.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T19:02:42.138124+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37069,"accession_number":"0001193125-26-391780","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Omnibus Equity Incentive Plan, a successor to the expired 2015 Plan. This is a compensatory arrangement for officers and directors involving equity grants and incentive awards. The filing explicitly references Item 5.02(e) context and describes the plan's governance and effectiveness, making it a material executive compensation disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T19:02:42.138124+00:00","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-09-15"},{"id":37070,"accession_number":"0001193125-26-391780","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Arcadia Biosciences' Annual Meeting held September 10, 2026. The filing reports final voting tallies on seven proposals including director election, equity issuance authorization, adoption of a 2026 Omnibus Equity Incentive Plan, reverse stock split authorization, advisory compensation vote, auditor ratification, and meeting adjournment. These results are material to investors as they reflect stockholder approval of significant corporate actions including potential dilutive equity issuances and reverse stock split authority.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T19:02:42.138124+00:00","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-09-15"}]}